Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated1
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

terminated133%
completed133%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
completed

Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients

NCT03409692
withdrawnearly_phase_1

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

NCT04285749
terminatedphase_2

Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

NCT00516750

Clinical Trials (3)

Showing 3 of 3 trials
NCT03409692

Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients

Completed
NCT04285749Early Phase 1

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Withdrawn
NCT00516750Phase 2

Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

Terminated

All 3 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
3